Survodutide for treatment of obesity: baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1) - Le Roux, Carel W.; Wharton, Sean; Bozkurt, Biykem; Platz, Elke; Bleckert, Gabriele; Ajaz Hussain, Samina; Brückmann, Martina; Startseva, Elena; Kloer, Isabel M.; Kaplan, Lee M. (Diabetes, obesity and metabolism, 2025)
Erstmals veröffentlicht: 4. November 2025